Voyager Therapeutics announced a strategic collaboration and capsid license agreement with Novartis Pharma to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy.
Voyager Therapeutics, a biotech company dedicated to advancing neurogenetic medicines, announced a strategic collaboration and capsid license agreement with Novartis Pharma, a subsidiary of Novartis to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will provide…